Early detection of chemotherapy-related left ventricular dysfunction

Current Cardiology Reports

Volumn 14, Issue 3, 2012, Pages 334-341

  De Cara, Jeanne M ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

Anthracycline; Cardiotoxicity; Chemotherapy; Echocardiography; Left ventricular dysfunction; Speckle tracking

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXORUBICIN; TRASTUZUMAB; TROPONIN I; TROPONIN T;

ARTICLE; BREAST CANCER; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL PRACTICE; DISEASE MODEL; DISEASE SURVEILLANCE; DOPPLER FLOWMETRY; EARLY DIAGNOSIS; ECHOCARDIOGRAPHY; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE CELL; HEART PROTECTION; HUMAN; MEDICAL ASSESSMENT; MEDICAL DECISION MAKING; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OXIDATIVE STRESS; SCINTIANGIOGRAPHY; SYMPTOM; THREE DIMENSIONAL ECHOCARDIOGRAPHY; TISSUE DOPPLER IMAGING; TRANSTHORACIC ECHOCARDIOGRAPHY; TWO DIMENSIONAL ECHOCARDIOGRAPHY;

ANTINEOPLASTIC AGENTS; BIOLOGICAL MARKERS; EARLY DIAGNOSIS; HUMANS; STROKE VOLUME; VENTRICULAR DYSFUNCTION, LEFT;

EID: 84861100820     PISSN: 15233782     EISSN: 15343170     Source Type: Journal    
DOI: 10.1007/s11886-012-0256-z     Document Type: Article

References (46)

1. Lefrak EA, Pitha J, Rosenheim S, Gottlieb JA. A clinicopathologic analysis of adriamycin cardiotoxicity Cancer. 1973;32(2):302-14.
2. Von Hoff DD, Layard MW, Basa P, et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med. 1979;91(5):710-7.
3. Yeh ET, Bickford CL. Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. J Am Coll Cardiol. 2009;53(24):2231-47. This is a comprehensive review of various chemotherapeutic agents and their cardiac toxicities.
4. Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer. 2003;97(11):2869-79.
5. Lipshultz SE, Alvarez JA, Scully RE. Anthracycline associated cardiotoxicity in survivors of childhood cancer. Heart. 2008;94(4):525-33.
6. Grenier MA, Lipshultz SE. Epidemiology of anthracycline cardiotoxicity in children and adults. Semin Oncol. 1998;25(4 Suppl 10):72-85.
7. Altena R, Perik PJ, van Veldhuisen DJ, de Vries EG, Gietema JA. Cardiovascular toxicity caused by cancer treatment: strategies for early detection. Lancet Oncol. 2009;10(4):391-9.
8. Steinherz LJ, Steinherz PG, Tan CT, Heller G, Murphy ML. Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA. 1991;266(12):1672-7.
9. Sawyer DB, Peng X, Chen B, Pentassuglia L, Lim CC. Mechanisms of anthracycline cardiac injury: can we identify strategies for cardioprotection? Prog Cardiovasc Dis. 2010;53(2):105-13. The basic science mechanisms underlying anthracycline injury are well described.
10. Billingham ME, Mason JW, Bristow MR, Daniels JR. Anthracycline cardiomyopathy monitored by morphologic changes. Cancer Treat Rep. 1978;62(6):865-72.
11. Mackay B, Ewer MS, Carrasco CH, Benjamin RS. Assessment of anthracycline cardiomyopathy by endomyocardial biopsy. Ultrastruct Pathol. 1994;18(1-2):203-11.
12. Saini J, Rich MW, Lyss AP Reversibility of severe left ventricular dysfunction due to doxorubicin cardiotoxicity. Report of three cases. Ann Intern Med. 1987;106(6):814-6.
13. Haq MM, Legha SS, Choksi J, et al. Doxorubicin-induced congestive heart failure in adults. Cancer. 1985;56(6):1361-5.
14. Hudziak RM, Schlessinger J, Ullrich A. Increased expression of the putative growth factor receptor p185HER2 causes transformation and tumorigenesis of NIH 3T3 cells. Proc Natl Acad Sci U S A. 1987;84(20):7159-63.
15. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235(4785):177-82.
16. Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989;244(4905):707- 12.
17. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353(16):1673-84.
18. Chien KR. Myocyte survival pathways and cardiomyopathy: implications for trastuzumab cardiotoxicity. Semin Oncol. 2000;27(6 Suppl 11):9-14. discussion 92-100.
19. Seidman A, Hudis C, Pierri MK, et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol. 2002;20(5):1215-21.
20. Ewer MS, Vooletich MT, Durand JB, et al. Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment. J Clin Oncol. 2005;23(31):7820-6.
21. Hunt SA, Abraham WT, Chin MH, et al. Focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation. J Am Coll Cardiol. 2009;53(15):e1-e90. These heart failure guidelines indicate that ACE inhibitors may be appropriate for patients receiving cardiac toxins.
22. Yoon GJ, Telli ML, Kao DP, Matsuda KY, Carlson RW, Witteles RM. Left ventricular dysfunction in patients receiving cardiotoxic cancer therapies are clinicians responding optimally? J Am Coll Cardiol. 2010;56(20):1644-50. In this provocative paper, the authors present single-center data suggesting that chemotherapyrelated LVD is not always treated optimally with conventional heart failure therapy or cardiologist consultation.
23. Cardinale D, Colombo A, Lamantia G, et al. Anthracyclineinduced cardiomyopathy: clinical relevance and response to pharmacologic therapy. J Am Coll Cardiol. 2010;55(3):213-20. These investigators demonstrate that contrary to prior belief, anthracycline-induced cardiomyopathy may respond to modern conventional heart failure therapy.
24. Noori A, Lindenfeld J, Wolfel E, Ferguson D, Bristow MR, Lowes BD. Beta-blockade in adriamycin-induced cardiomyopathy. J Card Fail. 2000;6(2):115-9.
25. Tallaj JA, Franco V, Rayburn BK, et al. Response of doxorubicininduced cardiomyopathy to the current management strategy of heart failure. J Heart Lung Transplant. 2005;24(12):2196-201.
26. Chu TF, Rupnick MA, Kerkela R, et al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet. 2007;370(9604):2011-9.
27. Khakoo AY, Kassiotis CM, Tannir N, et al. Heart failure associated with sunitinib malate: a multitargeted receptor tyrosine kinase inhibitor. Cancer. 2008;112(11):2500-8.
28. Lang RM, Bierig M, Devereux RB, et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr. 2005;18(12):1440-63.
29. Spencer KT, Bednarz J, Mor-Avi V, et al. The role of echocardiographic harmonic imaging and contrast enhancement for improvement of endocardial border delineation. J Am Soc Echocardiogr. 2000;13(2):131-8.
30. Malm S, Frigstad S, Sagberg E, Larsson H, Skjaerpe T. Accurate and reproducible measurement of left ventricular volume and ejection fraction by contrast echocardiography: a comparison with magnetic resonance imaging. J Am Coll Cardiol. 2004;44(5):1030-5.
31. Jacobs LD, Salgo IS, Goonewardena S, et al. Rapid online quantification of left ventricular volume from real-time three-dimensional echocardiographic data. Eur Heart J. 2006;27(4):460-8.
32. Walker J, Bhullar N, Fallah-Rad N, et al. Role of three-dimensional echocardiography in breast cancer: comparison with two-dimensional echocardiography, multiple-gated acquisition scans, and cardiac magnetic resonance imaging. J Clin Oncol. 2010;28(21):3429-36. The authors compare 2D and 3D echocardiography to cardiac MRI for the assessment of LVEF. They suggest that 3D echocardiography is superior to 2D echocardiography for precise and reproducible LVEF determination.
33. Cardinale D, Sandri MT, Martinoni A, et al. Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy. J Am Coll Cardiol. 2000;36(2):517-22.
34. Cardinale D, Sandri MT, Martinoni A, et al. Myocardial injury revealed by plasma troponin I in breast cancer treated with highdose chemotherapy. Ann Oncol. 2002;13(5):710-5.
35. Cardinale D, Sandri MT, Colombo A, et al. Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy. Circulation. 2004;109(22):2749-54.
36. Mor-Avi V, Lang RM, Badano LP, et al. Current and evolving echocardiographic techniques for the quantitative evaluation of cardiac mechanics: ASE/EAE consensus statement on methodology and indications endorsed by the Japanese Society of Echocardiography. J Am Soc Echocardiogr. 2011;24(3):277-313. This consensus statement describes the various echocardiographic techniques that are utilized to assess myocardial mechanics, along with their respective strengths and limitations.
37. Neilan TG, Jassal DS, Perez-Sanz TM, et al. Tissue Doppler imaging predicts left ventricular dysfunction and mortality in a murine model of cardiac injury. Eur Heart J. 2006;27(15):1868-75.
38. Jassal DS, Han SY, Hans C, et al. Utility of tissue Doppler and strain rate imaging in the early detection of trastuzumab and anthracycline mediated cardiomyopathy. J Am Soc Echocardiogr. 2009;22(4):418-24. These investigators demonstrate the value of echocardiographic indices of myocardial deformation in the early detection of chemotherapy-related LVD in an animal model.
39. Tassan-Mangina S, Codorean D, Metivier M, et al. Tissue Doppler imaging and conventional echocardiography after anthracycline treatment in adults: early and late alterations of left ventricular function during a prospective study. Eur J Echocardiogr. 2006;7(2):141-6.
40. Ho E, Brown A, Barrett P, et al. Subclinical anthracycline-and trastuzumab-induced cardiotoxicity in the long-term follow-up of asymptomatic breast cancer survivors: a speckle tracking echocardiographic study. Heart. 2010;96(9):701-7. This group of investigators used tissue Doppler and speckle tracking to compare strain patterns in patients exposed to anthracyclines or anthracyclines followed by trastuzumab to controls. They also examined serial diastolic parameters in each group.
41. Hare JL, Brown JK, Leano R, Jenkins C, Woodward N, Marwick TH. Use of myocardial deformation imaging to detect preclinical myocardial dysfunction before conventional measures in patients undergoing breast cancer treatment with trastuzumab. Am Heart J. 2009;158(2):294-301. These investigators demonstrate the value of tissue Doppler and speckle tracking echocardiography for the early detection of chemotherapy-related LVD in humans receiving trastuzumab.
42. Sawaya H, Sebag IA, Plana JC, et al. Early detection and prediction of cardiotoxicity in chemotherapy-treated patients. Am J Cardiol. 2011;107(9):1375-80. This study was the first to employ both biomarkers and echocardiographic parameters of myocardial deformation to detect LVD in patients receiving anthracyclines and trastuzumab. Sensitivity, specificity, positive and negative predictive values for TNI and global longitudinal strain are estimated.
43. Fallah-Rad N, Walker JR, Wassef A, et al. The utility of cardiac biomarkers, tissue velocity and strain imaging, and cardiac magnetic resonance imaging in predicting early left ventricular dysfunction in patients with human epidermal growth factor receptor II-positive breast cancer treated with adjuvant trastuzumab therapy. J Am Coll Cardiol. 2011;57(22):2263-70. These investigators were the first to combine multiple biomarkers, echocardiographic indices, and cardiac MRI with gadolinium enhancement for early detection of LVD in patients receiving trastuzumab. A pattern of delayed enhancement was found in the lateral wall of all 10 subjects who developed LVD.
44. Cardinale D, Colombo A, Sandri MT, et al. Prevention of highdose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation. 2006;114(23):2474-81. This study demonstrates the role of TNI to identify patients who will benefit from cardioprotective medication while receiving trastuzumab.
45. Bosch X, Esteve J, Sitges M, et al. Prevention of chemotherapyinduced left ventricular dysfunction with enalapril and carvedilol: rationale and design of the OVERCOME trial. J Card Fail. 2011;17(8):643-8. These investigators outline their intention to study the role of conventional heart failure therapy to prevent chemotherapy-induced cardiotoxicity in patients with hematological malignancies undergoing autologous stem cell transplant. They will incorporate cardiac MRI, echocardiographic parameters of myocardial deformation, and biomarkers into their serial patient assessment.
46. Pituskin E, Haykowsky M, Mackey JR, et al. Rationale and design of the Multidisciplinary Approach to Novel Therapies in Cardiology Oncology Research Trial (MANTICORE 101-Breast): a randomized, placebo-controlled trial to determine if conventional heart failure pharmacotherapy can prevent trastuzumab-mediated left ventricular remodeling among patients with HER2+ early breast cancer using cardiac MRI. BMC Cancer. 2011;11:318. This study will utilize cardiac MRI and biomarkers to study the effect of cardioprotective medications to prevent LVD in patients treated with trastuzumab.